A Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43 Recombinant Pseudomonas Vaccine Intensive Care Patients

Trial Profile

A Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43 Recombinant Pseudomonas Vaccine Intensive Care Patients

Completed
Phase of Trial: Phase II/III

Latest Information Update: 02 Jun 2016

At a glance

  • Drugs IC 43 (Primary) ; IC 43 (Primary)
  • Indications Pseudomonal infections; Respiratory tract infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Valneva
  • Most Recent Events

    • 02 Jun 2016 Results published in a Valneva media release.
    • 02 Jun 2016 Primary endpoint (number of deaths until Day 28) has not been met, according to a Valneva media release.
    • 29 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top